Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.

Exclusion Criteria

• •1. Patient treated with a gonadotrophin releasing hormone agonist, anti-estrogens, or aromatase inhibitors within 2 months prior to study entry.
• •2. Patient treated with estrogen pellets or progestin injectable drugs within 6 months prior to study entry.
• •3. Patient experience only nighttime hot flashes or worked night shifts on a regular basis.
• •4. Patient was concurrently treated with gabapentin for other indications. If patient was using gabapentin for treatment of hot flashes, she could be screened after a 7-day washout period provided hot flashes returned.
• •5. Patient had previously experienced dose-limiting adverse effects that prevented titration of gabapentin to an effective dose.
• •6. Patient had a hypersensitivity to gabapentin.
• •7. Patient was in an immunocompromised state.
• •8. Patient had a malignancy other than basal cell carcinoma within 2 years prior to study entry.
• •9. Patient had gastric reduction surgery, severe chronic diarrhea, chronic constipation, uncontrolled irritable bowel syndrome, uncontrolled inflammatory bowel disease, or unexplained weight loss.
• •10. Patient had clinically significant abnormal chemistry or hematology results, or calculated glomerular filtration rate \<60 mL/min.
• •11. Patient had history of substance abuse within year prior to study entry.
• •12. Patient was concurrently taking morphine.
• •13. Patient had history of chronic hepatitis B or C, hepatitis within 3 months prior to study entry, or history of human immunodeficiency virus.
• •Other Exclusions apply.